Immunomodulation of autoimmunity by linomide: Inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis

Journal of Neuroimmunology

Volumn 74, Issue 1-2, 1997, Pages 102-110

  Lehmann, Dan ^a   Karussis, Dimitrios M ^a   Fluresco, Dana ^a   Mizrachi Koll, Rachel ^a   Ovadia, Haim ^a   Shezen, Elias ^a   Kalland, Terje ^b   Abramsky, Oded ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Pharmacia & Upjohn AB   (Sweden)

Author keywords

antigen presentation; EAE; linomide

Indexed keywords

IMMUNOMODULATING AGENT; MERCAPTOETHANOL; ROQUINIMEX;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; IMMUNOMODULATION; MACROPHAGE ACTIVATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030890184     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(96)00211-1     Document Type: Article

References (33)

1. Bansil, S., Cook, S. and Rodowsky-Kochan, C. (1995) Multiple sclerosis: Immune mechanism and update on current therapies. Ann. Neurol. 37(S1), S87-S101.
2. Barany, G. and Merrifield, R.B. (1980) The peptide. In: eds. E. Gross and J. Meienhofer, The Peptide, Vol. 2. Academic Press, New York, NY.
3. Ben-Nun, A., Wekerle, H. and Cohen, I.R. (1981) The rapid isolation of clonable antigen-specific T-lymphocytes lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 11, 195-199.
4. Bengtsson, M., Simonsson, B., Carlsson, K., Nilsson, B., Smedmyr, B., Teramander, B., Oberg, G. and Totterman, T. (1992) Stimulation of NK cell, T-cell and monocyte functions by the novel immunomodulator linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia. Transplantation 53, 882-888.
5. Bjork, J. and Kleinau, S. (1989) Paradoxical effects of LS-2616 (linomide) treatment in the type II collagen arthritis model in mice. Agents Actions 27, 319-321.
6. Borgstrom, P., Torres Filho, I.P., Vajkoczy, P., Strandgarden, K., Polacek, J. and Hartley-Asp, B. (1994) The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo. Cancer Chemother. Pharmacol. 34, 280-286.
7. Diebler, G.E., Martenson, R.E. and Kies, M.W. (1972) Large scale preparation of MBP from central nervous tissue of several mammalian species. Prep. Biochem. 2, 139-165.
8. Harning, R., Koo, G.C. and Szalay, J. (1990) Immune regulation of metastasis from in vivo derived syngeneic murine melanoma. Reg. Immunol. 3, 97-102.
9. Harning, R., Koo, G.C. and Szalay, J. (1989) Regulation of the metastasis of murine ocular melanoma by natural killer cells. Invest. Ophthalmol. Vis. Sci. 30, 1909-1915.
10. Harning, R. and Szalay, J. (1988) A treatment for metastasis of murine ocular melanoma. Invest. Ophthalmol. Vis. Sci. 29, 1505-1510.
11. Huitinga, I., R.N. van, G.C. de, Uitdehaag, B.M. and Dijkstra C.D. (1990) Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J. Exp. Med. 172, 1025-1033.
12. Ichikawa, T., Lamb, J.C., Christensson, P.I., Hartley-Asp, B. and Isaacs, J.T. (1992) The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res. 52, 3022-3028.
13. Ilback, N.G., Fohlan, J., Slorach, S. and Friman, G. (1989) Effects of the immunomodulator LS 2616 on lymphocyte subpopulations in murine Coxsackie virus B3 myocarditis. J. Immunol. 142, 3225-3228.
14. Kalland, T., Alm, G. and Stalhandske, T. (1985) Augmentation of mouse natural killer activity by LS-2616, a new immunomodulator. J. Immunol. 134, 3956-3961.
15. Kalland, T. (1986) Effects of immunomodulator LS2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res. 46, 3018-3022.
16. Kalland, T. (1990) Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J. Immunol. 144, 4472-4476.
17. Karussis, D.M., Slavin, S., Lehmann, D., Vourka-Karussis, U., Mizrachi-Koll, R., Ovadia, H., Kalland, T. and Abramsky, O. (1993a) Successful treatment of chronic-relapsing experimental autoimmune encephalomyelitis with linomide (LS-2616), a synthetic immunomodulator. Proc. Natl. Acad. Sci. USA 90, 6400-6404.
18. Karussis, D.M., Vourka-Karussis, U., Lehmann, D., Ovadia, H., Mizrachi-Koll, R., Slavin, S. and Abramsky O. (1993b) Inhibition of experimental autoimmune encephalomyelitis with linomide (LS-2616), a synthetic immunomodulator. Ann. Neurol. 34, 654-660.
19. Karussis, D.M., Lehmann, D., Brenner, T., Wirguin, I., Mizrachi, K.R., Sicsic, C. and Abramsky, O. (1994) Immunomodulation of experimental autoimmune myasthenia gravis with linomide. J. Neuroimmunol. 55, 187-193.
20. Karussis, D.M., Lehmann, D., Slavin, S., Kalland, T., Vourka-Karussis, U., Mizrachi-Koll, R., Ovadia, H. and Abramsky, O. (1995) Immunomodulation of autoimmunity by linomide. Isr. J. Med. Sci. 31, 38-41.
21. Karussis, D.M., Meiner, Z., Lehmann, D., Gomori, J.-M., Schwarz, A., Linde, A. and Abramsky. O. (1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: A double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 47, 341-346.
22. Kleinau, S., Larsson, P., Bjork, J., Holmdahl, R. and Klareskog, L. (1989) Linomide, a new immunomodulatory drug, shows different effects on homologous versus heterologous collagen induced arthritis in rats. Clin. Exp. Immunol. 78, 138-142.
23. Larsson, E.L., Joki, A. and Stalhandske, T. (1987) Mechanism of action of the new immunomodulator LS-2616 on T-cell responses. Int. J. Immunopharmacol. 9, 425-431.
24. Lehmann, D., Karussis, D.M., Ovadia, H., Misrachi-Koll, R. and Abramsky, O. (1994) Oral administration of the oxidant's scavenger N-acetyl-cysteine protect mice against EAE. J. Neuroimmunol. 50, 35-42.
25. McCarron, R.M., Fallis, R.J. and McFarlin, D.E. (1990) Alterations in T-cell antigen specificity and class II restriction during the course of chronic relapsing experimental allergic encephalomyelitis. J. Neuroimmunol. 29, 73-79.
26. Nilsson, B.I. (1988) Phase I study in malignancy of LS 2616, a new immunomodulator: methodological considerations. Cancer Detect. Prev. 12, 553-559.
27. Slavin, S., Sidi, H., Weiss, L., Rosenman, E., Kalland, T. and Gross, D. (1993) Linomide, a new treatment for autoimmune diseases: the potential in type 1 diabetes. Diabetes Metab. Rev. 9, 311-315.
28. Spetz-Hagberg, A.L., Goldschmidt, T.J., Stalhandske, T. and Larsson-Sciard, E.L. (1990) Amelioration of intrathymic T-cell development and peripheral T-cell reactivities in autoimmune mice undergoing therapy with a novel immunomodulator. Int. Immunol. 2, 645-650.
29. Stalhandske, T., Eriksson, E. and Sandberg, B.M. (1982) A novel quinoline-carboxamide with interesting immunomodulating activity. Int. J. Immunopharmacol. 4, 336.
30. Stalhandske, T. and Kalland, T. (1986) Effects of the novel immunomodulator LS 2616 on the delayed-type hypersensitivity reaction to Bordetella Pertussis in the rat. Immunopharmacology 11, 87-92.
31. Tarkowski, A., Gurnarsson, K. and Stalhandske, T. (1986a) Effects of LS-2616 administration upon the autoimmune disease of (NZBXNZW)F1 hybrid mice. Immunology 59, 589-594.
32. Tarkowski, A., Gunnarsson, K., Nilsson, L.A., Lindholm, L. and Stalhandske, T. (1986b) Successful treatment of autoimmunity in MRL/J mice with LS-2616, a new immunomodulator. Arthritis Rheum. 29, 1405-1409.
33. Vukanovic, J., Passaniti, A., Hirata, T., Traystman, R.J., Hartley-Asp, B. and Isaacs, J.T. (1993) Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res. 53, 1833-1837.